Uptake of sentinel lymph node biopsy following a melanoma diagnosis: an Australian population-based study

Oct 1, 2026 |Surgical Oncology

 

Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma - The early Australian experience

Claimed Authorship Spillane, Andrew

Jul 26, 2026 |European Journal of Cancer

 

Utility of recurrence-based surrogate endpoints for survival in adjuvant cancer trials: evidence from melanoma

Claimed Authorship Spillane, Andrew J.

Jun 15, 2026 |Journal of the National Cancer Institute

 

NeoIRENIE: A phase 2 randomized trial of intensified neoadjuvant therapy for melanoma patients with multi-omic biomarker or clinically predicted poor response to standard immune checkpoint inhibitor (ICI) therapy

Claimed Authorship Spillane, Andrew J.

Jun 1, 2026 |Journal of Clinical Oncology

 

A phase 2 study of neoadjuvant nivolumab (nivo) plus relatlimab (rela) in high-risk stage II cutaneous melanoma (NeoReNi)

Claimed Authorship Spillane, Andrew J.

Jun 1, 2026 |Journal of Clinical Oncology

 

A phase 3, international, multicenter, randomized, controlled trial of selective index lymph node resection versus therapeutic lymph node dissection after neoadjuvant immunotherapy for stage IIIB-D melanoma (MSLT-3/S2601/EORTC2519)

Claimed Authorship Spillane, Andrew J.

Jun 1, 2026 |Journal of Clinical Oncology

 

Characteristics of melanomas in individuals of South-East and East Asian ancestry

Claimed Authorship Spillane, Andrew

May 1, 2026 |Australasian Journal of Dermatology

 

Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial

Claimed Authorship Spillane, Andrew J.

Mar 1, 2026 |Nature Medicine

 

Timing of Definitive Surgical Management of Primary Cutaneous Melanoma: Association With Survival

Claimed Authorship Spillane, Andrew J.

Mar 1, 2026 |ANZ Journal of Surgery

 

Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanoma

Claimed Authorship Spillane, A. J.

Feb 1, 2026 |Annals of Oncology

 

Accuracy of PET/CT in the diagnosis of pelvic lymph node metastases in melanoma: A subgroup analysis of the prospective, randomised, phase III Evaluation of groin lymphadenectomy extent for metastatic melanoma (EAGLE-FM) trial

Claimed Authorship Spillane, Andrew

Jan 1, 2026 |European Journal of Surgical Oncology (EJSO)

 

Evolving Practices in Breast Cancer Surgery: Findings From the Australian Targeted Axillary Dissection Registry

Claimed Authorship Spillane, Andrew J.

Jan 1, 2026 |ANZ Journal of Surgery

 

Changes in patient management after preoperative MRI for newly diagnosed breast cancer: a multicentre prospective observational study

Claimed Authorship Spillane, Andrew

Dec 8, 2025 |Medical Journal of Australia

 

Current pattern of care in radiation therapy for DCIS in Australia - where are we heading? (vol 82, 104482, 2025)

Claimed Authorship Spillane, Andrew J.

Dec 1, 2025 |The Breast

 

A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials

Claimed Authorship Spillane, Andrew J.

Oct 28, 2025 |npj Breast Cancer

 

A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma

Claimed Authorship Spillane, Andrew

Oct 16, 2025 |European Journal of Cancer

 

Cutaneous Melanoma Management-An Update and Narrative Review for the General Surgeon

Claimed Authorship Spillane, Andrew

Oct 1, 2025 |ANZ Journal of Surgery

 

Association between circulating tumour DNA and FDG-PET as biomarkers of response to neoadjuvant therapy in stage III melanoma

Claimed Authorship Spillane, A. J.

Sep 1, 2025 |Annals of Oncology

 

Long-term outcome of adding the histone deacetylase inhibitor (HDACi) domatinostat (DOM) to neoadjuvant (neoadj) nivolumab (NIVO) plus /- ipilimumab (IPI) in interferon-gamma signature (IFNg) high/low stage III melanoma patients (pts)

Claimed Authorship Spillane, A. J.

Sep 1, 2025 |Annals of Oncology

 

Nodal radioactivity after lymphoscintigraphy as a guide to sentinel node-positivity in melanoma patients

Claimed Authorship Spillane, Andrew J.

Sep 1, 2025 |European Journal of Surgical Oncology (EJSO)

 

Longitudinal Analysis Reveals Dynamic Changes in Histopathologic Features in Responders to Neoadjuvant Treatment in a Stage III BRAF-Mutant Melanoma Cohort

Claimed Authorship Spillane, Andrew J.

Aug 1, 2025 |Modern Pathology

 

ASO Visual Abstract: Cartilage Resection in the Surgical Management of Ear Melanoma

Claimed Authorship Spillane, Andrew J.

Aug 1, 2025 |Annals of Surgical Oncology

 

Current pattern of care in radiation therapy for DCIS in Australia and New Zealand - where are we heading?

Claimed Authorship Spillane, Andrew J.

Aug 1, 2025 |The Breast

 

Economic Evaluation of Inguinal Versus Ilio-inguinal Lymphadenectomy for Patients with Stage III Metastatic Melanoma to Groin Lymph Nodes: Evidence from the EAGLE FM Randomized Trial (feb, 10.1245/s10434-025-17040-2, 2025)

Claimed Authorship Spillane, Andrew J.

Jul 1, 2025 |Annals of Surgical Oncology

 

Cartilage Resection in the Surgical Management of Ear Melanoma

Claimed Authorship Spillane, Andrew J.

Jul 1, 2025 |Annals of Surgical Oncology

 

ASO Visual Abstract: Economic Evaluation of Inguinal Versus Ilio-inguinal Lymphadenectomy for Patients with Stage III Metastatic Melanoma to Groin Lymph Node: Evidence from the EAGLE FM Randomized Trial

Claimed Authorship Spillane, Andrew J.

Jul 1, 2025 |Annals of Surgical Oncology

 

Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous Melanoma

Claimed Authorship Spillane, Andrew J.

Jun 1, 2025 |JAMA Dermatology

 

Setting a precedent: Development of a core outcome set for locoregional treatment outcome reporting in neoadjuvant breast cancer trials

Claimed Authorship Spillane, Andrew J.

Jun 1, 2025 |Journal of Clinical Oncology

 

Economic Evaluation of Inguinal Versus Ilio-inguinal Lymphadenectomy for Patients with Stage III Metastatic Melanoma to Groin Lymph Nodes: Evidence from the EAGLE FM Randomized Trial

Claimed Authorship Spillane, Andrew J.

Jun 1, 2025 |Annals of Surgical Oncology

 

Diagnostic Potential of ⁶⁸Ga-NeoB PET/CT with Estrogen Receptor-and Progesterone Receptor-Positive Breast Cancer Undergoing Staging or Restaging for Metastatic Disease

Claimed Authorship Spillane, Andrew

May 1, 2025 |Journal of Nuclear Medicine

 

Integrating ctDNA and FDG-PET dynamics to predict pathological response following neoadjuvant systemic therapy in stage III melanoma Free

Claimed Authorship Spillane, Andrew J.

Apr 15, 2025 |Cancer Research

 

Spatial and multiomics analysis reveals immune interactions as key drivers of immunotherapy outcomes in melanoma patients with in-transit metastases

Claimed Authorship Spillane, Andrew J.

Apr 15, 2025 |Cancer Research

 

FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma

Claimed Authorship Spillane, Andrew J.

Mar 25, 2025 |Journal for ImmunoTherapy of Cancer

 

Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance (vol 40, pg 88, 2022)

Claimed Authorship Spillane, Andrew J.

Mar 10, 2025 |Cancer Cell

 

Surgical considerations around neoadjuvant therapy in melanoma: surgical outcomes from the randomized phase 3 Nadina trial

Claimed Authorship Spillane, Andrew

Mar 1, 2025 |Annals of Surgical Oncology

 

Surrogate Endpoints for Clinical Trial Design in Early-Stage Primary Cutaneous Melanoma Staged with Sentinel Node Biopsy: an International, Multicenter Cohort Study

Claimed Authorship Spillane, Andrew

Mar 1, 2025 |Annals of Surgical Oncology

 

Clinical significance of intra-thoracic and intra-abdominal sentinel lymph nodes detected on lymphoscintigraphy in truncal melanoma patients

Claimed Authorship Spillane, Andrew J.

Feb 1, 2025 |European Journal of Surgical Oncology (EJSO)

 

Single breast incision for breast conservation surgery and sentinel lymph node biopsy: a systematic review

Claimed Authorship Spillane, Andrew J.

Jan 31, 2025 |ANZ Journal of Surgery

 

Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo

Claimed Authorship Spillane, Andrew J.

Jan 1, 2025 |European Journal of Cancer

 

Robotic Transabdominal Preperitoneal Inguinal Hernia Repair Is Feasible and Efficient: A Prospective Cohort Study of a Day-Only Protocol From a High-Volume Robotic Surgery Centre Evaluating Short-Term Outcomes

Claimed Authorship Spillane, Andrew

Jan 1, 2025 |ANZ Journal of Surgery

Impact of an online risk prediction tool for sentinel node metastasis on clinical decision-making in melanoma care: A mixed methods study

Claimed Authorship Spillane, Andrew J.

Dec 1, 2024 |Surgical Oncology Insight

 

Patient and Staff Experiences of Embedding Electronic Patient Reported Outcome Measures for Distress Screening and Quality of Life Assessment, Into Routine Melanoma Care: A Mixed-Methods Study

Claimed Authorship Spillane, Andrew

Dec 1, 2024 |Psycho-Oncology

 

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma

Claimed Authorship Spillane, Andrew

Nov 7, 2024 |New England Journal of Medicine

 

Health-related quality-of-life in neoadjuvant combinations of immunotherapy in BRAF^V600-mutant resectable melanoma: Results from the randomised phase II neotrio trial

Claimed Authorship Spillane, Andrew J.

Nov 1, 2024 |Asia-Pacific Journal of Clinical Oncology

 

Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging

Claimed Authorship Spillane, Andrew J.

Oct 23, 2024 |Annals of Surgical Oncology

 

Optimising the targeted axillary dissection in breast cancer: marker type and timing variability

Claimed Authorship Spillane, Andrew J.

Oct 1, 2024 |Gland Surgery

 

Exploring locoregional treatment reporting in neoadjuvant systemic breast cancer treatment studies: A systematic review☆

Claimed Authorship Spillane, Andrew

Oct 1, 2024 |European Journal of Surgical Oncology (EJSO)

 

Impact of an Online Risk Calculator for Sentinel Node Positivity on Management of Patients with T1 and T2 Melanomas

Claimed Authorship Spillane, Andrew J.

Sep 1, 2024 |Annals of Surgical Oncology

 

High concurrent interferon gamma signature expression in the primary tumor and lymph node metastasis is associated with superior outcome upon neoadjuvant ipilimumab plus nivolumab in stage III melanoma

Claimed Authorship Spillane, A. J.

Sep 1, 2024 |Annals of Oncology

 

Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAF^V600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial

Claimed Authorship Spillane, Andrew J.

Sep 1, 2024 |Nature Medicine

 

High concurrent interferon gamma signature expression in the primary tumor and lymph node metastasis is associated with superior outcome upon neoadjuvant ipilimumab plus nivolumab in stage III melanoma

Claimed Authorship Spillane, A. J.

 

Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma

Claimed Authorship Spillane, A. J.

Aug 1, 2024 |Annals of Oncology

 

The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma; An Australian Cohort

Claimed Authorship Spillane, Andrew J.

Aug 1, 2024 |Annals of Surgical Oncology

 

Impact of an Online Risk Calculator for Sentinel Node Positivity on Management of Patients with T1 and T2 Melanomas

Claimed Authorship Spillane, Andrew J.

Aug 1, 2024 |Annals of Surgical Oncology

 

ASO Visual Abstract: The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma: An Australian Cohort

Claimed Authorship Spillane, Andrew J.

Aug 1, 2024 |Annals of Surgical Oncology

 

ASO Author Reflections: Impact of an Online Risk Calculator for Sentinel Node Positivity on Management of Patients with T1 and T2 Melanomas

Claimed Authorship Spillane, Andrew J.

Aug 1, 2024 |Annals of Surgical Oncology

 

ASO Visual Abstract: Leg Lymphoedema After Inguinal and Ilio-Inguinal Lymphadenectomy for Melanoma: Results from a Prospective Randomized Trial

Claimed Authorship Spillane, A. J.

Jul 1, 2024 |Annals of Surgical Oncology

 

FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma

Claimed Authorship Spillane, Andrew John

Jun 1, 2024 |Journal of Clinical Oncology

 

A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage I to III resectable Merkel cell carcinoma (Neo-MCC)

Claimed Authorship Spillane, Andrew John

Jun 1, 2024 |Journal of Clinical Oncology

 

Incidence and risk factors for central nervous system (CNS) metastasis (met) in patients (pts) with stage III melanoma treated with adjuvant (ADJ) anti-PD1 immunotherapy (IMT)

Claimed Authorship Spillane, Andrew John

Jun 1, 2024 |Journal of Clinical Oncology

 

Leg Lymphoedema After Inguinal and Ilio-Inguinal Lymphadenectomy for Melanoma: Results from a Prospective, Randomised Trial

Claimed Authorship Spillane, A. J.

Jun 1, 2024 |Annals of Surgical Oncology

 

Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator

Claimed Authorship Spillane, Andrew J.

Apr 1, 2024 |Journal of Clinical Oncology

 

Protocol for the development of a core outcome set and reporting guidelines for locoregional treatment in neoadjuvant systemic breast cancer treatment trials: the PRECEDENT project

Claimed Authorship Spillane, Andrew

Apr 1, 2024 |BMJ Open

 

An Externally Validated Online Tool To Calculate Personalized Probabilities Of Recurrence-Free And Overall-Survival In Stage II Melanoma Patients

Claimed Authorship Spillane, Andrew

Mar 1, 2024 |Annals of Surgical Oncology

 

Innovation in Collaborating and Funding an International Cancer Clinical Trial

Claimed Authorship Spillane, Andrew

Mar 1, 2024 |Annals of Surgical Oncology

 

Timing of definitive surgical treatment of primary cutaneous melanoma: impact on survival

Claimed Authorship Spillane, Andrew

Mar 1, 2024 |Annals of Surgical Oncology

 

Surgical considerations for resecting the index lymph node after neo-adjuvant checkpoint inhibitors: lessons learned from the PRADO trial

Claimed Authorship Spillane, Andrew

Mar 1, 2024 |Annals of Surgical Oncology

 

Current bi-national attitudes towards targeted axillary dissection

Claimed Authorship Spillane, Andrew J.

Feb 1, 2024 |ANZ Journal of Surgery

 

Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study

Claimed Authorship Spillane, Andrew J.

Jan 20, 2024 |The Lancet

 

The complexities of establishing a surgical multi-centre registry in Australia: challenges, and possible solution

Claimed Authorship Spillane, Andrew J.

Jan 1, 2024 |ANZ Journal of Surgery

 

ASO Author Reflections: Lymphoedema Related to Inguinal and Ilioinguinal Lymphadenectomy for Melanoma

Claimed Authorship Spillane, A. J.

Jan 1, 2024 |Annals of Surgical Oncology

Benefits and harms of breast cancer screening revisited: a large, retrospective cross-sectional study quantifying treatment intensity in women with screen-detected versus non-screen-detected cancer in Australia and New Zealand

Claimed Authorship Spillane, Andrew J.

Dec 22, 2023 |BMJ Oncology

 

ASO Visual Abstract: Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging

Claimed Authorship Spillane, Andrew J.

Dec 20, 2023 |Annals of Surgical Oncology

 

Prognostic Significance of Incipient Ulceration in Primary Cutaneous Melanoma

Claimed Authorship Spillane, Andrew J.

Dec 1, 2023 |JAMA Dermatology

 

Patient-reported health-related quality of life outcomes following mastectomy for breast cancer, with immediate, delayed or no breast reconstruction: Four-year follow-up from a prospective cohort study

Claimed Authorship Spillane, Andrew

Oct 1, 2023 |The Breast

 

Women's views about current and future management of Ductal Carcinoma in Situ (DCIS): A mixed-methods study

Claimed Authorship Spillane, Andrew

Jul 21, 2023 |Plos One

 

Adjuvant radiotherapy after salvage surgery for melanoma recurrence in a node field following a previous lymph node dissection

Claimed Authorship Spillane, Andrew J.

Jul 1, 2023 |Journal of Surgical Oncology

 

Utility of next generation sequencing for differentiating malignant PEComa from metastatic melanoma

Claimed Authorship Spillane, Andrew J.

Jun 1, 2023 |Pathology

 

A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in high-risk stage II cutaneous melanoma: NeoReNi II

Claimed Authorship Spillane, Andrew John

Jun 1, 2023 |Journal of Clinical Oncology

 

The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo

Claimed Authorship Spillane, Andrew John

Jun 1, 2023 |Journal of Clinical Oncology

 

Improving Selection for Sentinel Lymph Node Biopsy Among Patients With Melanoma

Claimed Authorship Spillane, Andrew J.

Apr 19, 2023 |JAMA Network Open

 

Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach

Claimed Authorship Spillane, Andrew J.

Apr 13, 2023 |Journal of Translational Medicine

 

The association between melanoma liver metastases (mets) and the systemic anti-tumor immune profile

Claimed Authorship Spillane, Andrew J.

Apr 1, 2023 |Cancer Research

 

Predictive biomarker models of immunotherapy response in patients with metastatic melanoma: genomic, transcriptomic, and immune profiles from the Personalised Immunotherapy Program (PIP)

Claimed Authorship Spillane, Andrew J.

Apr 1, 2023 |Cancer Research

 

Prognostic Significance and Management of Sentinel Nodes in the Triangular Intermuscular Space of Patients with Melanoma

Claimed Authorship Spillane, Andrew

Apr 1, 2023 |Annals of Surgical Oncology

 

ASO Visual Abstract: Prognostic Significance and Management of Sentinel Nodes in the Triangular Intermuscular Space of Patients with Melanoma

Claimed Authorship Spillane, Andrew

Apr 1, 2023 |Annals of Surgical Oncology

 

TRENDS AND VARIATIONS IN POST-MASTECTOMY BREAST RECONSTRUCTION RATES IN AUSTRALIA OVER 10 YEARS

Claimed Authorship Spillane, Andrew

Apr 1, 2023 |The Breast

 

USING RADIO-OCCULT LESION LOCALIZATION (ROLL) TECHNIQUES TO IDENTIFY THE CLIPPED NODE IN TARGETED AXILLARY DISSECTIONS (TAD)

Claimed Authorship Spillane, Andrew

Apr 1, 2023 |The Breast

 

IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma

Claimed Authorship Spillane, Andrew J.

Mar 15, 2023 |Journal of Experimental Medicine

 

Validating the Use of Surrogate Endpoints to Assess the Survival Outcomes of Melanoma Patients in Clinical Trials

Claimed Authorship Spillane, Andrew

Mar 1, 2023 |Annals of Surgical Oncology

 

Trends and variations in post-mastectomy breast reconstruction rates in Australia over 10 years

Claimed Authorship Spillane, Andrew

Jan 18, 2023 |ANZ Journal of Surgery

Association between body mass index and adverse surgical outcomes of implant-based breast reconstruction: a prospective cohort study of 5,545 breast reconstructions

Claimed Authorship Spillane, Andrew

Dec 30, 2022 |Annals of Breast Surgery

 

Embedding electronic patient-reported outcome measures into routine care for patients with stage III MELanoma (ePROMs-MEL): protocol for a prospective, longitudinal, mixed-methods pilot study

Claimed Authorship Spillane, Andrew

Dec 20, 2022 |BMJ Open

 

Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes

Claimed Authorship Spillane, Andrew J.

Dec 2, 2022 |Cancer Discovery

 

Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome

Claimed Authorship Spillane, Andrew J.

Nov 1, 2022 |Nature Medicine

 

Radio-isotope occult lesion localization (ROLL) techniques to identify the clipped node for targeted axillary dissection (TAD) in breast cancer

Claimed Authorship Spillane, Andrew J.

Nov 1, 2022 |ANZ Journal of Surgery

 

Primary results of ANZ 1002: Post-operative Radiotherapy Omission in Selected Patients with Early breast Cancer Trial (PROSPECT) following pre-operative breast MRI

Claimed Authorship Spillane, A.

Nov 1, 2022 |European Journal of Cancer

 

Factors influencing acceptance, adoption and adherence to sentinel node biopsy recommendations in the Australian Melanoma Management Guidelines: a qualitative study using an implementation science framework

Claimed Authorship Spillane, Andrew J.

Oct 1, 2022 |Implementation Science Communications

 

Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases

Claimed Authorship Spillane, Andrew

Oct 1, 2022 |Annals of Surgical Oncology

 

ASO Visual Abstract: Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-transit Melanoma Metastases

Claimed Authorship Spillane, Andrew

Oct 1, 2022 |Annals of Surgical Oncology

Neotrio trial - optimal neoadjuvant sequencing of anti-PD1 and BRAF targeting therapy in resectable BRAF mutant stage IIIB/C/D melanoma: results of histopathological analysis

Claimed Authorship Spillane, A.

Oct 1, 2022 |Histopathology

Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites

Claimed Authorship Spillane, Andrew J.

Sep 12, 2022 |Journal for ImmunoTherapy of Cancer

 

Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting

Claimed Authorship Spillane, Andrew J.

Sep 5, 2022 |Journal of Translational Medicine

 

Relapse-free survival (RFS) update and first translational analyses of DONIMI, a study testing personalized neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage III melanoma patients (pts) based on the interferon-gamma signature (IFN-γ sign) algorithm

Claimed Authorship Spillane, A. J.

Sep 1, 2022 |Annals of Oncology

 

NeoTrio - Optimal neoadjuvant (NAT) sequencing of anti-PD-1 and BRAF targeted therapy (TT) in BRAF mutant stage III melanoma: Results of histopathological analysis

Claimed Authorship Spillane, A. J.

Sep 1, 2022 |Annals of Oncology

 

Longitudinal analysis of circulating immune cell subsets in melanoma patients (pts) treated with neo-adjuvant ipilimumab (ipi) & nivolumab (nivo)

Claimed Authorship Spillane, A. J.

Sep 1, 2022 |Annals of Oncology

 

A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma

Claimed Authorship Spillane, A. J.

Sep 1, 2022 |Annals of Oncology

NeoPeLe: A phase II trial of neoadjuvant (NAT) pembrolizumab (Pembro) combined with lenvatinib (Lenva) in resectable stage III melanoma

Claimed Authorship Spillane, A. J.

Sep 1, 2022 |Annals of Oncology

 

Sentinel lymph node biopsy rates in Victoria, 2018 and 2019

Claimed Authorship Spillane, Andrew

Aug 15, 2022 |Medical Journal of Australia

 

Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC) (Jan, 10.1245/S10434-021-11236-Y, 2022)

Claimed Authorship Spillane, Andrew J.

Aug 1, 2022 |Annals of Surgical Oncology

 

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Claimed Authorship Spillane, Andrew J.

Jun 5, 2022 |Nature Medicine

 

Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

Claimed Authorship Spillane, Andrew J.

Jun 1, 2022 |Annals of Surgical Oncology

 

NeoTrio: Randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D plus T) in resectable BRAF-mutant stage III melanoma to determine optimal combination of therapy

Claimed Authorship Spillane, Andrew John

Jun 1, 2022 |Journal of Clinical Oncology

 

Survival data of PRADO: A phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma

Claimed Authorship Spillane, Andrew John

Jun 1, 2022 |Journal of Clinical Oncology

 

Multi-Trait Genetic Analysis Identifies Autoimmune Loci Associated with Cutaneous Melanoma

Claimed Authorship Spillane, Andrew

Jun 1, 2022 |Journal of Investigative Dermatology

 

Neoadjuvant dabrafenib and trametinib (D plus T) for stage III melanoma: Long-term results from the NeoCombi trial

Claimed Authorship Spillane, Andrew John

Jun 1, 2022 |Journal of Clinical Oncology

 

Primary results of ANZ 1002: Post-operative radiotherapy omission in selected patients with early breast cancer trial (PROSPECT) following pre-operative breast MRI

Claimed Authorship Spillane, Andrew John

Jun 1, 2022 |Journal of Clinical Oncology

 

Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes

Claimed Authorship Spillane, Andrew

May 1, 2022 |European Journal of Cancer

 

Original Research Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patients

Claimed Authorship Spillane, Andrew

May 1, 2022 |European Journal of Cancer

 

Melanoma Margins Trial (MelMarT-II) Evaluating 1 cm vs 2cm Wide Local Excision Margins for Patients with Primary Cutaneous Melanomas

Claimed Authorship Spillane, Andrew J.

May 1, 2022 |Annals of Surgical Oncology

Randomized trial of neoadjuvant chemotherapy with or without concurrent aromatase inhibitor therapy to downstage ER plus ve breast cancer: Breast Cancer Trials Group ANZ 1401 ELIMINATE trial

Claimed Authorship Spillane, A.

May 1, 2022 |Annals of Oncology

 

Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma

Claimed Authorship Spillane, Andrew J.

Apr 1, 2022 |JAMA Surgery

 

Breast Radiotherapy after Oncoplastic Surgery-A Multidisciplinary Approach

Claimed Authorship Spillane, Andrew

Apr 1, 2022 |Cancers

 

BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting

Claimed Authorship Spillane, Andrew J.

Feb 1, 2022 |Pathology

 

Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance

Claimed Authorship Spillane, Andrew J.

Jan 10, 2022 |Cancer Cell

 

The role of breast reconstruction choice on body image patient-reported outcomes at four years post-mastectomy for breast cancer: A longitudinal prospective cohort study

Claimed Authorship Spillane, Andrew

Jan 1, 2022 |Psycho-Oncology